Cost-benefit analysis of influenza vaccination in a public healthcare unit

Therapeutics and Clinical Risk Management

Volumn 2, Issue 2, 2006, Pages 219-226

  Colombo, Giorgio L ^a   Ferro, Antonio ^b   Vinci, Marta ^a   Zordan, Maria ^b   Serra, Giulio ^a  

^a SAVE Studi Analisi Valutazioni Economiche   (Italy)

^b Unità Locale Socio Sanitaria ULSS no 17   (Italy)

Author keywords

Economic evaluation; Influenza vaccination strategy; Observational study

Indexed keywords

INFLUENZA VACCINE;

ABSENTEEISM; ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EMPLOYEE; FEMALE; HEALTH CARE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PUBLIC HEALTH; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

EID: 33745448527     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.2.219     Document Type: Article

References (42)

1. Akazawa M, Sindelar JL, Paltiel AD. 2003. Economic costs of influenza-related work absenteeism. Value Health, 6:107-15.
2. Allsup S, Gosney M, Haycox A, et al. 2003. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. Health Technol Assess, 7:iii-x, 1-65.
3. Berger K, Szucs TD. 1999. Socioeconomic evaluation in medicine in Europe. Core economic concepts. Pharmacoeconomics, 16(Suppl 1):19-25.
4. Birch S, Gafni A, O'Brien B. 1999. Willingness to pay and the valuation of programmes for the prevention and control of influenza. Pharmacoeconomics, 16(Suppl 1):55-61.
5. Bridges CB, Harper SA, Fukuda K, et al; Advisory Committee on Immunization Practices. 2003. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 52(RR-8):1-34; quiz CE1-4.
6. Brisson M, Edmunds WJ. 2003. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making, 23:76-82.
7. Campbell DS, Rumley MH. 1997. Cost effectiveness of the influenza vaccine in a healthy working age population. J Occup Environ Med, 39:408-14.
8. Colombo GL, Nicosia V, Lesma A, et al. 2001. Analisi costi-benefici di una strategia vaccinale antinfluenzale condotta presso una società del gruppo ENI (Snamprogetti). Pharmacoeconomics Italian Research Articles, 3:71-80.
9. Das Gupta R, Guest JF. 2002. A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac® in the UK. Pharmacoeconomics, 20:475-84.
10. Demicheli V, Jefferson T, Rivetti D, et al. 2000. Prevention and early treatment of influenza in healthy adults. Vaccine, 18:957-1030.
11. Freund DA, Dittus RS. 1992. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics, 1:20-32.
12. Gallo G, Ciofi degli Atti ML, Cerquetti M, et al. 2002. Impact of a regional Hib vaccination programme in Italy. Vaccine, 20:993-5.
13. Gardener P, Schaffner W. 1993. Immunisation in adults. N Engl J Med, 338:1252-8.
14. Gasparini R, Lucioni C, Lai P, et al. 2003. Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in Liguria. Pharmacoeconomics Italian Research Articles, 5(Suppl 1):23-30.
15. Gasparini R, Lucioni C, Lai P, et al. 2002. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine, 20(Suppl 5):B50-4.
16. Gasparini R, Pozzi T, Bonanni P. 2000. Valutazione dei costi di un'epidemia influenzale nella popolazione lavorativa di Siena. Giornale di Farmacoeconomia, 1:3-9.
17. Johannesson M, Karlsson G. 1997. The friction cost method: a comment. J Health Econ, 16:249-55.
18. Keech M, Scott AJ, Ryan PJ. 1998. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond), 48:85-90.
19. Koopmanschap MA, Rutten FFH. 1996a. Indirect costs: the consequence of productivity loss or increased cost of production. Med Care, 34(Suppl):DS59-68.
20. Koopmanschap MA, Rutten FFH. 1996b. A practical guide for calculating indirect costs of disease. Pharmacoeconomics, 10:460-6.
21. Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. 1995. The friction cost method for measuring indirect costs of disease. J Health Econ, 14:171-89.
22. Kumpulainen V, Makela M. 1997. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis, 29:181-5.
23. Landi F, Onder G, Cesari M, et al. 2003. Effects of influenza vaccination on mortality among frail, community-living elderly patients: an observational study. Aging Clin Exp Res, 15:254-8.
24. Lee PY, Matchar DB, Dennis A, et al. 2002. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med, 137:225-31.
25. Levy E. 1996. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics, 9(Suppl 3):62-6.
26. Ministero della Salute. 2003. Prevenzione e controllo dell'influenza: raccomandazioni per la stagione 2003-2004. Ministero della Salute; Circolare n. 5 del 22 luglio.
27. Montomoli E, Pozzi T, Alfonsi V, et al. 2003. Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in due stagioni epidemiche a confronto nella provincia di Siena. Pharmacoeconomics Italian Research Articles, 5(Suppl 1):31-8.
28. Nichol KL, Goodman M. 1999. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. Pharmacoeconomics, 16(Suppl 1):63-71.
29. Nichol KL, Lind A, Margolis KL, et al. 1995. The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med, 333:889-93.
30. Nichol KL, Mallon KP, Mendelman PM. 2003. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine, 21:2207-17.
31. Nicholson KG. 1998. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, (eds). Textbook of Influenza. London: Blackwell Sci Ltd.
32. Olsen GW, Burris JM, Burlew MM, et al. 1998. Absenteeism among employees who participated in a workplace influenza immunization program. J Occup Environ Med, 40:311-16.
33. Postma MJ, Bos JM, Van Gennep M. 1999. Economic evaluation of influenza vaccination. Pharmacoeconomics, 16(Suppl 1):33-40.
34. Postma MJ, Jansema P, Marianne LL, et al. 2002. Pharmacoeconomics of influenza vaccination for healthy working adults. Drugs, 62:1015-24.
35. Principi N, Esposito S. 2004. Are we ready for universal influenza vaccination in paediatrics? Lancet Infect Dis, 4:75-83.
36. Rychlik R, Heinen-Kammerer T, Rusche H, et al. 2003. Cost-effectiveness of prophylaxis and treatment of influenza. Dtsch Med Wochenschr, 128:2267-70.
37. Schnoor JL. 2003. Internalizing the externalities. Environ Sci Technol, 37:159A.
38. Sloan FA. 1995. Valuing healthcare. Cambridge: Cambridge Univ Pr.
39. Turner D, Wailoo A, Nicholson K, et al. 2003. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess, 7: iii-iv, xi-xiii, 1-170.
40. Warburton MF, Jacobs DS, Langsford WA, et al. 1972. Herd immunity following subunit influenza vaccine administration. Med J Aust, 2:67-70.
41. Webster RG. 2000. Immunity to influenza in the elderly. Vaccine, 18:1686-9.
42. Wilde JA, McMillan JA, Serwint J, et al. 1999. Effectiveness of influenza vaccine in healthcare professionals. JAMA, 281:908-13.